Gail Wilensky, PhD, senior fellow, Project Hope, says that larger payers are introducing plans that reward consumers for choosing high-quality healthcare clinicians with lower co-payments and premiums. Dr Wilensky also says that there are many attempts to slow spending and improve quality.
Gail Wilensky, PhD, senior fellow, Project Hope, says that larger payers are introducing plans that reward consumers for choosing high-quality healthcare clinicians with lower co-payments and premiums. Dr Wilensky also says that there are many attempts to slow spending and improve quality. "We are relatively early in the process with a lot of promising change going on, but it will take a few years to see how much of what we see is sustainable," said Dr Wilensky.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More